Boryung Pharmaceutical received their first sales approval of hypertensive treatment 'Kanarb' in Mexico
On May 27, Boryung Pharmaceutical announced that they received their first sales approval of hypertensive treatment 'Kanarb' from the COFEPRIS/The Federal Commission for the Protection against Sanitary Risk in Mexico.
According to the Boryung Pharmaceutical, they signed a licensing out contract ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
